The popularity of Viagra initially drove a surge for pharma, but recent shifts present a complicated scenario for investors. Lower-cost competitors are reducing revenue, and continued patent challenges add additional complexity to the situation. While certain companies could still see gains from adjacent services, the general trajectory suggests… Read More